

**INFORMATION DISCLOSURE
STATEMENT BY APPLICANT**
(Not for submission under 37 CFR 1.99)

Application Number	10524470
Filing Date	2006-02-28
First Named Inventor	Eatherton et al.
Art Unit	1624
Examiner Name	D. Rao
Attorney Docket Number	P33099USw

U.S.PATENTS

Examiner Initial*	Cite No	Patent Number	Kind Code ¹	Issue Date	Name of Patentee or Applicant of cited Document	Pages, Columns, Lines where Relevant Passages or Relevant Figures Appear
	1	6184237	A	2001-02-06	Mantlo et al.	
	2	6107301	A	2000-08-22	Aldrich et al.	

If you wish to add additional U.S. Patent citation information please click the Add button.

U.S.PATENT APPLICATION PUBLICATIONS

Examiner Initial*	Cite No	Publication Number	Kind Code ¹	Publication Date	Name of Patentee or Applicant of cited Document	Pages, Columns, Lines where Relevant Passages or Relevant Figures Appear
	1					

If you wish to add additional U.S. Published Application citation information please click the Add button.

FOREIGN PATENT DOCUMENTS

Examiner Initial*	Cite No	Foreign Document Number ³	Country Code ² j	Kind Code ⁴	Publication Date	Name of Patentee or Applicant of cited Document	Pages, Columns, Lines where Relevant Passages or Relevant Figures Appear	T ⁵
	1							<input type="checkbox"/>

If you wish to add additional Foreign Patent Document citation information please click the Add button

NON-PATENT LITERATURE DOCUMENTS

ALL REFERENCES CONSIDERED EXCEPT WHERE LINED THROUGH. /DR/

**INFORMATION DISCLOSURE
STATEMENT BY APPLICANT**
(Not for submission under 37 CFR 1.99)

Application Number	10524470
Filing Date	2006-02-28
First Named Inventor	Eatherton et al.
Art Unit	1624
Examiner Name	D. Rao
Attorney Docket Number	P33099USw

Examiner Initials*	Cite No	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc), date, pages(s), volume-issue number(s), publisher, city and/or country where published.	T ⁵
	1	IWAMURA H. ET AL.; "In vitro and in vivo pharmacological characterization of JTE-907, a novel selective ligand for cannabinoid CB2 receptor."; Journal of Pharmacology and Experimental Therapeutics; 2001; 296(2); 420-425;	<input type="checkbox"/>
	2	MALAN, T.P. ET AL.; "CB2 Cannabinoid Receptor Agonists: Pain Relief Without Psychoactive Effects?"; Current Opinion in Pharmacology; 2003; 3; 62-67;	<input type="checkbox"/>
	3	VAN DER MEY M. ET AL.; "Novel selective PDE4 inhibitors. 3. In vivo antiinflammatory activity of a new series of N-substituted cis-tetra- and cis-hexahydrophthalazinones."; Journal of Pharmacology and Experimental Therapeutics; 2001; 45(12); 2520-2525;	<input type="checkbox"/>
	4	HOHMANN, A.G. ET AL.; "Spinal and Peripheral Mechanisms of Cannabinoid Antinociception: Behavioral, Neurophysiological and Neuroanatomical Perspectives"; Chemistry and Physics of Lipids; 2002; 121; 173-190;	<input type="checkbox"/>
	5	FARQUHAR-SMITH, W.P. ET AL.; "Administration of Endocannabinoids Prevents a Referred Hyperalgesia Associated with Inflammation of the Urinary Bladder"; Anesthesiology; 2001; 94; 507-513;	<input type="checkbox"/>
	6	JAGGAR, S.I. ET AL.; "The Anti-Hyperalgesic Actions of the Cannabinoid Anandamide and the Putative CB2 Receptor Agonist Palmitoylethanolamide in Visceral and Somatic Inflammatory Pain"; Pain; 1998; 76; 189-199;	<input type="checkbox"/>
	7	KEHL, L.J. ET AL.; "A cannabinoid Agonist Differentially Attenuates Deep Tissue Hyperalgesia in Animal Models of Cancer and Inflammatory Muscle Pain"; Pain; 2003; 103; 175-186;	<input type="checkbox"/>
	8	GOYA, P. ET AL.; "Cannabinoids and Neuropathic Pain"; Mini Reviews in Medicinal Chemistry; 2003; 3; 765-772;	<input type="checkbox"/>
	9	YAO, B.B. ET AL.; "In Vitro and In Vivo Characterization of A-796260: A Selective Cannabinoid CB2 Receptor Agonist Exhibiting Analgesic Activity in Rodent Pain Models"; British Journal of Pharmacology; 2006; 153; 390-401;	<input type="checkbox"/>
	10	PERTWEE, R.G. ET AL.; "Cannabinoid Receptors and Pain"; Progress in Neurobiology; 2001; 63; 569-611;	<input type="checkbox"/>

ALL REFERENCES CONSIDERED EXCEPT WHERE LINED THROUGH. /DR/

**INFORMATION DISCLOSURE
STATEMENT BY APPLICANT**
(Not for submission under 37 CFR 1.99)

Application Number		10524470
Filing Date		2006-02-28
First Named Inventor	Eatherton et al.	
Art Unit	1624	
Examiner Name	D. Rao	
Attorney Docket Number	P33099USw	

11	JHAVERI, M.D. ET AL.; "Cannabinoid CB2 Receptor-Mediated Anti-nociception in Models of Acute and Chronic Pain"; Molecular Neurobiology; 2007; 36; 26-35;	<input type="checkbox"/>
12	IZZO A.A. ET AL.; "The Cannabinoid CB2 Receptor: A Good Friend in the Gut"; Neurogastroenterology Motility; 2007; 19; 704-708;	<input type="checkbox"/>
13	MALAN, T.P. ET AL.; "Inhibition of Pain Responses By Activation of CB2 Cannabinoid Receptors"; Chemistry and Physics of Lipids; 2002; 121; 191-200;	<input type="checkbox"/>

If you wish to add additional non-patent literature document citation information please click the Add button

EXAMINER SIGNATURE

Examiner Signature	/Deepak Rao/	Date Considered	07/20/2009
--------------------	--------------	-----------------	------------

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through a citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ See Kind Codes of USPTO Patent Documents at www.USPTO.GOV or MPEP 901.04. ² Enter office that issued the document, by the two-letter code (WIPO Standard ST.3). ³ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁴ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. ⁵ Applicant is to place a check mark here if English language translation is attached.

ALL REFERENCES CONSIDERED EXCEPT WHERE LINED THROUGH. /DR/